tiprankstipranks
Noxopharm Ltd. (AU:NOX)
ASX:NOX
Australian Market

Noxopharm Ltd. (NOX) Share Price & Analysis

1 Followers

NOX Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.03 - AU$0.17
Previous CloseAU$0.06
Volume60.42K
Average Volume (3M)189.15K
Market Cap
AU$18.12M
Enterprise ValueAU$4.27M
Total Cash (Recent Filing)AU$14.01M
Total Debt (Recent Filing)AU$160.62K
Price to Earnings (P/E)-1.5
Beta-0.51
Aug 29, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares OutstandingN/A
10 Day Avg. Volume1,326,352
30 Day Avg. Volume189,145
Standard Deviation0.31
R-Squared0.08
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

16.07%0.00%0.00%83.93%
16.07% Insiders
0.00% Other Institutional Investors
83.93% Public Companies and
Individual Investors

NOX FAQ

What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.03 and its highest was AU$0.17 in the past 12 months.
    What is Noxopharm Ltd.’s market cap?
    Currently, no data Available
    When is Noxopharm Ltd.’s upcoming earnings report date?
    Noxopharm Ltd.’s upcoming earnings report date is Aug 29, 2024 which is in 113 days.
      How were Noxopharm Ltd.’s earnings last quarter?
      Noxopharm Ltd. released its earnings results on Feb 26, 2024. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
        Is Noxopharm Ltd. overvalued?
        According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Noxopharm Ltd. pay dividends?
          Noxopharm Ltd. does not currently pay dividends.
          What is Noxopharm Ltd.’s EPS estimate?
          Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Noxopharm Ltd. have?
          Noxopharm Ltd. has 292,237,950 shares outstanding.
            What happened to Noxopharm Ltd.’s price movement after its last earnings report?
            Noxopharm Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.286%.
              Which hedge fund is a major shareholder of Noxopharm Ltd.?
              Currently, no hedge funds are holding shares in AU:NOX
              ---

              Noxopharm Ltd. Stock Smart Score

              5
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -17.80%
              12-Months-Change

              Fundamentals

              Return on Equity
              -95.95%
              Trailing 12-Months
              Asset Growth
              -67.35%
              Trailing 12-Months

              Company Description

              Noxopharm Ltd.

              Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Vectus Biosystems Limited
              Chimeric Therapeutics Ltd.
              Race Oncology Ltd.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis